Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins

Generic Name: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins

Drug Type: Biotech

Unique Ingredient Identifier: 3ME9TTI5QB

Background: Adipose mesenchymal stem cells (AMSCs) are MSCs derived from adipose tissue, which is more accessible and less painful than stem cells extracted from most other sources. Autologous stem cells are those derived from a patient’s own cells while allogeneic stem cells are derived from that of a donor. Lipoaspiration, also known as liposuction, is a possible method for extraction. This is followed by purification and expansion of the cells in vitro.

These AMSCs are multipotent, with the capability of forming different tissues, some of which include bone, muscle, neural, and chondrocyte. This explains why AMSCs have been utilized in repairing craniofacial bone defects. They also have potential in treatment of scarred vocal folds.

Clinical Trials

"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"

Phase 2

Conditions: Relapsing Remitting Multiple Sclerosis (RRMS)
Multiple Sclerosis

Interventions: Drug: Autologous HB-adMSCs

First Posted Date: 2025-01-30

Last Posted Date: 2025-04-03

Lead Sponsor: Hope Biosciences

Target Recruit Count: 10

Registration Number: NCT06800404

Locations: 🇺🇸
Hope Biosciences Research Foundation, Sugar Land, Texas, United States

Stem Cell Therapy for Early Alzheimer's Disease

Phase 1

Not yet recruiting

Conditions: Cognitive Dysfunction

Interventions: Biological: adMSC

First Posted Date: 2025-01-15

Last Posted Date: 2025-01-31

Lead Sponsor: Paul E Schulz

Target Recruit Count: 12

Registration Number: NCT06775964

Locations: 🇺🇸
The University of Texas Health Science Center at Houston (UTHealth), Houston, Texas, United States

Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury

Phase 1

Not yet recruiting

Conditions: Acute Kidney Injury

Interventions: Drug: Normal Saline
Drug: Allogeneic HB-adMSCs

First Posted Date: 2024-10-23

Last Posted Date: 2025-01-23

Lead Sponsor: Hope Biosciences

Target Recruit Count: 70

Registration Number: NCT06654193

Locations: 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
The University of Texas Health Science Center at Houston (UTHealth Houston), Houston, Texas, United States

Dose Escalation of Allogeneic Adipose Derived Stroma/Stem Cells for the Treatment of Crohn's Fistula

Phase 1

Not yet recruiting

Conditions: Crohn Disease

Interventions: Drug: AdMSC (CellReady®)

First Posted Date: 2024-10-10

Last Posted Date: 2024-10-10

Lead Sponsor: University Hospital, Toulouse

Target Recruit Count: 9

Registration Number: NCT06636032

Locations: 🇫🇷
Toulouse Hospital, Toulouse, France

Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

Phase 2

Recruiting

Conditions: Traumatic Brain Injury

Interventions: Drug: Normal Saline
Biological: Autologous HB-adMSCs

First Posted Date: 2023-07-19

Last Posted Date: 2025-05-07

Lead Sponsor: Hope Biosciences

Target Recruit Count: 51

Registration Number: NCT05951777

Locations: 🇺🇸
Memorial Hermann Hospital / UTHealth McGovern Medical School at Houston, Houston, Texas, United States
🇺🇸
The University of Texas Health Science at San Antonio, San Antonio, Texas, United States